In Brief: FoxMeyer
FoxMeyer: Dissatisfaction with joint ownership with Phar-Mor CEO Robert Haft of Hamilton Morgan, a limited liability company whose sole investment is a 31% stake in Phar-Mor, prompts FoxMeyer to invoke buy/sell option. Should Haft buy FoxMeyer's 69.8% stake in Hamilton Morgan, the wholesaler would realize cash proceeds of $26.6 mil.; should Haft sell his stake, his proceeds would total $7.2 mil...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth